---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038098"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:16:35.399425+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Delcath Q2 revenue jumps 210% to $24.2M; net income $2.7M vs loss; FY25 guidance raised

## Summary
- Total revenue $24.2M (+210% YoY); HEPZATO KIT revenue $22.5M, CHEMOSAT $1.7M.
- Net income $2.7M vs net loss $13.7M; Non-GAAP adj. EBITDA $9.8M vs loss $0.8M.
- FY2025 revenue guidance raised to $93-96M; gross margins 83-85%; positive EBITDA and cashflow each quarter.
- Cash and investments $81.0M, no debt; activated 3 new U.S. centers (20 total, 10 accepting referrals).
- Received EU/UK authorization for clinical study of HEPZATO in metastatic colorectal cancer.

## SEC filing metadata
- accession: 0001628280-25-038098
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828025038098/0001628280-25-038098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828025038098/dcth-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038098
- JSON: https://secwatch.observer/filing/0001628280-25-038098.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.